# US 2019/0376053 A1 · Collagen-binding agent compositions and methods of using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0376053 A1
- Document ID: US20190376053A1
- Status: Published application
- Kind: A1
- Application number: 16/485,290
- Filed: 2018-02-09
- Published: 2019-12-12
- Earliest claimed: 2017-02-10
- Assignees: Board of Trustees of the University of Arkansas; The Kitasato Institute
- Applicants: The Board of Trustees of the University of Arkansas; The Kitasato Institute
- Inventors: Joshua SAKON; Jeffrey ROESER; Ryan BAUER; Katarzyna JANOWSKA; Keisuke TANAKA; Osamu MATSUSHITA; Kentaro UCHIDA
- Web page: https://patentgrep.com/patent/US20190376053A1

## CPC

- C12N 9/52: derived from bacteria {or Archaea}
- A61K 8/64: Proteins; Peptides; Derivatives or degradation products thereof
- A61K 8/65: Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
- A61K 8/66: Enzymes
- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61K 38/1825: {Fibroblast growth factor [FGF]}
- A61K 38/29: Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
- A61K 47/6415: {Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins}
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61Q 7/00: Preparations for affecting hair growth
- A61Q 19/08: Anti-ageing preparations
- C07K 14/475: Growth factors; Growth regulators
- C07K 14/50: Fibroblast growth factor [FGF]
- C07K 14/503: {basic FGF [bFGF]}
- C07K 14/51: Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
- C07K 14/635: Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
- C07K 14/71: for growth factors; for growth regulators
- C12Y 304/24003: Microbial collagenase (3.4.24.3)
- C07K 14/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- C07K 2319/00: Fusion polypeptide
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

The invention generally relates to collagen-binding agent compositions and methods of using the same. More specifically, the invention relates in part to new collagen-binding agent compositions and methods that may be used to treat damaged collagen within tissues or used to specifically target therapeutics to tissues containing undamaged or damaged collagen.

## Claims

### Claim 1

A collagen-binding therapeutic agent comprising two collagen-binding domains linked by a domain linker and a therapeutic agent linked to at least one of the collagen-binding domains by a therapeutic agent linker, wherein the collagen-binding agent lacks collagenase activity, and wherein each of the two collagen-binding domains are selected from the group consisting of any one of the polypeptides of SEQ ID NOs: 1-39, a polypeptide having at least 90% sequence identity to any one of SEQ ID NOs: 1-39, and a fragment of at least 8 consecutive amino acids of any one of SEQ ID NOs: 1-39,

### Claim 2 (depends on 1)

The collagen-binding agent of claim 1, wherein the therapeutic agent is selected from the group consisting of FGF, parathyroid hormone (PTH), PTH/PTHrP receptor agonist, PTH/PTHrP receptor antagonist, bone morphogenic protein (BMP), G-CSF, BMP-2, BMP-3, anti-sclerostin antibody, growth hormone, IGF-1, VEGF, TGF-β, KGF, TGF-α, TGF-β1, TGF-β receptor, CT, GH, GM-CSF, EGF, PDGF, celiprolol, activins and connective tissue growth factors.

### Claim 3 (depends on 1)

The collagen-binding agent of claim 1, wherein one of the collagen-binding domains is selected from the group consisting of the polypeptides of any one of SEQ ID NOs: 15-30, a polypeptide having at least 90% sequence identity to any one of SEQ ID NOs: 15-30, and a fragment of at least 8 consecutive amino acids of any one of SEQ ID NOs: 15-30 and wherein the other collagen-binding domain is selected from the group consisting of the polypeptides any one of SEQ ID NOs: 1-14 and 31-39, a polypeptide having at least 90% sequence identity to any one of SEQ ID NOs: 1-14 and 31-39, or a fragment of at least 8 consecutive amino acids of any one of SEQ ID NOs: 1-14 and 31-39.

### Claim 4 (depends on 1)

The collagen-binding agent of claim 1, wherein the two collagen-binding domains are selected from the group consisting of any one of SEQ ID NOs: 15-30, a polypeptide having at least 90% sequence identity to any one of SEQ ID NOs: 15-30, and a fragment of at least 8 consecutive amino acids of any one of SEQ ID NOs: 15-30.

### Claim 5 (depends on 1)

The collagen-binding agent of claim 1, wherein the two collagen-binding domains are selected from the group consisting of the polypeptides of any one of SEQ ID NOs: 1-14 and 31-39, a polypeptide having at least 90% sequence identity to any one of SEQ ID NOs: 1-14 and 31-39, or a fragment of at least 8 consecutive amino acids of any one of SEQ ID NOs: 1-14 and 31-39.

### Claim 6 (depends on 1)

The collagen-binding agent of claim 1, wherein the collagen-binding agent comprises a polypeptide selected from the group consisting of any one of the polypeptides of SEQ ID NOs: 40-47, a polypeptide having at least 90% sequence identity to any one of SEQ ID NOs: 40-47, and a fragment of at least 8 consecutive amino acids of any one of SEQ ID NOs: 40-47.

### Claim 7 (depends on 1)

The collagen-binding agent of claim 1, wherein the domain linker comprises a polypeptide.

### Claim 8 (depends on 1)

The collagen-binding agent of claim 1, wherein the domain linker comprises a polypeptide selected from the group consisting of any one of the polypeptides of SEQ ID NOs: 48-55 or a polypeptide having at least 80% sequence identity to any one of the polypeptides of SEQ ID NOs: 48-55.

### Claim 9 (depends on 1)

The collagen-binding agent of claim 1, wherein the therapeutic agent is selected from the group consisting of a polypeptide, a hormone, a growth factor, a cytokine, a small molecule, a polynucleotide, a carbohydrate, and a lipid.

### Claim 10 (depends on 1)

The collagen-binding agent of claim 1, wherein the therapeutic agent comprises a polypeptide.

### Claim 11 (depends on 1)

The collagen-binding agent of claim 1, wherein the therapeutic agent is selected from the group consisting of FGF, parathyroid hormone (PTH), PTH/PTHrP receptor agonist, and PTH/PTHrP receptor antagonist.

### Claim 12 (depends on 1)

The collagen-binding agent of claim 1, wherein the therapeutic agent linker comprises a polypeptide.

### Claim 13 (depends on 10)

The collagen-binding agent of claim 10, wherein the C terminus of the therapeutic agent is linked to the N-terminus of the collagen-binding agent by the therapeutic agent linker.

### Claim 14 (depends on 1)

A pharmaceutical composition comprising of the collagen-binding agents of claim 1 and a pharmaceutical carrier.

### Claim 15 (depends on 1)

A method of treating a condition comprising administering the collagen-binding agents of claim 1 to a subject in an amount effective to treat the condition.

### Claim 16 (depends on 15)

The method of claim 15, wherein the subject is a mammal.

### Claim 17 (depends on 16)

The method of claim 16, wherein the mammal is a human.

### Claim 18 (depends on 15)

The method of claim 15, wherein the condition is selected from the group consisting of hyperparathyroidism, a hair condition (either excessive hair growth or hair loss), a collagenopathy, a wound, a bone condition, spinal fusion, ischemic heart diseases, peripheral nerve disorder and spinal cord injury.

### Claim 19 (depends on 15)

The method of claim 15, wherein the condition comprises a collagenopathy selected from the group consisting of osteogenesis imperfecta, Stickler's syndrome, Ehlers-Danlos syndrome, Alport's syndrome, Caffey's disease, and localized collagen or cartilage damage.

### Claim 20

(canceled)
